There are currently 115 clinical trials in Pasadena, California looking for participants to engage in research studies. Trials are conducted at various facilities, including Keck Medical Center of USC Pasadena, Huntington Memorial Hospital, California Liver Research Institute and Lotus Clinical Research, LLC. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants with Active Thyroid Eye Disease (TED)
NCT06625411
Recruiting
This is a clinical trial assessing the efficacy, safety, and tolerability of an investigational drug, VRDN-003, in participants with active Thyroid Eye Disease (TED).
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/26/2025
Locations: Pasadena Clinical Trials, Pasadena, California
Conditions: Thyroid Eye Disease
Register for Updates
Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study)
NCT05516498
Recruiting
This is a two part Phase IIa/b multicentre, randomised, double-blind, placebo-controlled, parallel group dose-ranging study to assess the efficacy, safety, and tolerability of the combination of zibotentan and dapagliflozin, and dapagliflozin monotherapy versus placebo in participants with cirrhosis with features of portal hypertension.
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
03/24/2025
Locations: Research Site, Pasadena, California
Conditions: Liver Cirrhosis
Register for Updates
A Trial to Test the Safety and Efficacy of TEV-53408 in Treating Vitiligo
NCT06625177
Recruiting
The primary objective of the trial is to evaluate the safety of TEV-53408 administered subcutaneously for the treatment of adults with vitiligo. A secondary objective is to further evaluate the safety of TEV-53408. The planned study period per participant is 84 weeks including a screening period (up to 4 weeks), a 24-week open-label treatment period, a 16-week washout period, and a 40-week follow-up period.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
03/19/2025
Locations: Teva Investigational Site 12046, Pasadena, California
Conditions: Vitiligo
Register for Updates
Efficacy and Safety Study of Halneuron in the Treatment of Chemotherapy-Induced Neuropathic Pain
NCT06848348
Recruiting
A randomized study to determine safety and efficacy of single subcutaneous (SC) administration of HAL treatment in patients with CINP.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: Profound Research LLC, Pasadena, California
Conditions: Chemotherapy Induced Neuropathic Pain
Register for Updates
RGX-314 Gene Therapy Administered in the Suprachoroidal Space for Participants With Diabetic Retinopathy (DR) With and Without Center Involved-Diabetic Macular Edema (CI-DME)
NCT04567550
Recruiting
ABBV-RGX-314 is being developed as a novel, potential one-time gene therapy treatment for the treatment of Diabetic Retinopathy (DR) with and without Center-Involved Diabetic Macular Edema (CI-DME). DR is a chronic and progressive complication of diabetes mellitus. It is a sight-threatening disease characterized in the early stages by neuronal and vascular dysfunction in the retina, and later by neovascularization that leads to further deterioration of functional vision. Despite the availability... Read More
Gender:
ALL
Ages:
Between 25 years and 89 years
Trial Updated:
03/14/2025
Locations: California Eye Specialists Medical Group, Inc, Pasadena, California
Conditions: Diabetic Retinopathy (DR), Center-Involved Diabetic Macular Edema (CI-DME)
Register for Updates
A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1)
NCT05511363
Recruiting
This is a Phase 3, 38-week, randomized, double-blind, placebo-controlled, multicenter, outpatient study in subjects with psychosis associated with Alzheimer's Disease. The primary objective of the study is to evaluate relapse prevention in subjects with psychosis associated with Alzheimer's Disease treated with KarXT compared to placebo. The secondary objectives of the study are to evaluate the time from randomization to discontinuation for any reason and safety and tolerability in subjects wit... Read More
Gender:
ALL
Ages:
Between 55 years and 90 years
Trial Updated:
03/10/2025
Locations: SC3 Research - Pasadena - 960 E. Green St, Pasadena, California
Conditions: Psychosis Associated With Alzheimer's Disease
Register for Updates
FebriDx® Method Comparison Study Protocol
NCT06746259
Recruiting
The goal of this observational study is to learn about the performance and ease of use of FebriDx when operated by persons without laboratory experience or training in patients with acute respiratory symptoms. The main question it aims to answer is: • Is FebriDx accurate at differentiating bacterial from non-bacterial respiratory infections when used by untrained operators? Trained and untrained participants will run the FebriDx test on patients with respiratory symptoms to evaluate comparabili... Read More
Gender:
ALL
Ages:
Between 12 years and 64 years
Trial Updated:
03/03/2025
Locations: Exer Urgent Care, Pasadena, California
Conditions: Acute Respiratory Infections (ARIs)
Register for Updates
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
NCT05147220
Recruiting
To compare the efficacy and safety of remibrutinib versus teriflunomide in patients with relapsing multiple sclerosis (RMS)
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
02/28/2025
Locations: SC3 Research Pasadena, Pasadena, California
Conditions: Relapsing Multiple Sclerosis
Register for Updates
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 75 Years With gMG.
NCT06517758
Recruiting
The study is a randomized, double-blind, placebo-controlled, multicenter, Phase III study, to evaluate efficacy, safety and tolerability of iptacopan in patients with AChR+ gMG who are on stable SOC treatment. Participants who meet the eligibility criteria will be randomized in a ratio of 1:1, to receive either iptacopan or matching placebo, for 6 months (180 days) while continuing on a stable SOC treatment. The randomization will be stratified based on region.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
02/28/2025
Locations: SC3 Research Pasadena, Pasadena, California
Conditions: Generalized Myasthenia Gravis
Register for Updates
Open-Label Extension Study of Saroglitazar Magnesium in Participants with Primary Biliary Cholangitis
NCT06427395
Recruiting
Open-Label Extension Study of Saroglitazar Magnesium in Participants With Primary Biliary Cholangitis
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: Zydus US011, Pasadena, California
Conditions: Primary Biliary Cholangitis
Register for Updates
Amplatzer Amulet LAAO Vs. NOAC
NCT04226547
Recruiting
The objective of this trial is to evaluate the safety and effectiveness of the Amulet LAA occluder compared to NOAC therapy in patients with non-valvular AF at increased risk for ischemic stroke and who are recommended for long-term NOAC therapy. The clinical investigation is a prospective, randomized, multicenter active control worldwide trial. Subjects will be randomized in a 1:1 ratio between the Amulet LAA occlusion device ("Device Group") and a commercially available NOAC medication ("Cont... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/25/2025
Locations: Huntington Memorial Hospital, Pasadena, California
Conditions: Atrial Fibrillation, Stroke, Bleeding
Register for Updates
Anticoagulation in ICH Survivors for Stroke Prevention and Recovery
NCT03907046
Recruiting
Primary Aim: To determine if apixaban is superior to aspirin for prevention of the composite outcome of any stroke (hemorrhagic or ischemic) or death from any cause in patients with recent ICH and atrial fibrillation (AF). Secondary Aim: To determine if apixaban, compared with aspirin, results in better functional outcomes as measured by the modified Rankin Scale.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/24/2025
Locations: Huntington Memorial Hospital, Pasadena, California
Conditions: Intracerebral Hemorrhage, Atrial Fibrillation
Register for Updates